Sichuan Kelun-Biotech Biopharmaceutical Future Growth
Future criteria checks 5/6
Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 9.1% and 26.7% per annum respectively. EPS is expected to grow by 6.7% per annum. Return on equity is forecast to be -1.6% in 3 years.
Key information
9.1%
Earnings growth rate
6.7%
EPS growth rate
| Biotechs earnings growth | 28.6% |
| Revenue growth rate | 26.7% |
| Future return on equity | -1.6% |
| Analyst coverage | Good |
| Last updated | 26 Aug 2024 |
Recent future growth updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27Recent updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,593 | -141 | -80 | 97 | 14 |
| 12/31/2025 | 1,674 | -614 | -561 | -341 | 14 |
| 12/31/2024 | 1,824 | -212 | -494 | -558 | 13 |
| 6/30/2024 | 1,877 | -187 | -567 | -480 | N/A |
| 3/31/2024 | 1,709 | -354 | -295 | -210 | N/A |
| 12/31/2023 | 1,540 | -522 | -23 | 60 | N/A |
| 9/30/2023 | 1,523 | -427 | 135 | 207 | N/A |
| 6/30/2023 | 1,505 | -333 | 292 | 355 | N/A |
| 3/31/2023 | 1,155 | -440 | -9 | 42 | N/A |
| 12/31/2022 | 804 | -548 | -310 | -271 | N/A |
| 12/31/2021 | 32 | -823 | -581 | -486 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6990 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: 6990 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6990 is expected to become profitable in the next 3 years.
Revenue vs Market: 6990's revenue (26.7% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 6990's revenue (26.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6990 is forecast to be unprofitable in 3 years.